Top Abstract Purchase Related
Home
>
Node
>
Subnode

Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis

Sugiyama, E.

Clinical Calcium 17(4): 528-534

2007

ISSN/ISBN: 0917-5857
PMID: 17404481
Document Number: 605886
Matrix metalloproteinase-3 (MMP-3) , which is induced by inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) in rheumatoid synovium, degrades a number of extracellular matrix components of cartilage, and plays central roles in rheumatoid joint destruction. In addition, serum MMP-3 level is a clinically useful maker for predicting joint destruction and for disease activity in rheumatoid arthritis (RA) . In this review, I summarized the role of MMP-3 in rheumatoid joint destruction, and clinical usefulness of serum MMP-3 level as a laboratory marker in RA.

Document emailed within 1 workday
Secure & encrypted payments

Yamanaka, H. 2002: Usefulness of serum matrix metalloproteinase-3(MMP-3) level in the diagnosis of rheumatoid arthritis Nihon Rinsho. Japanese Journal of Clinical Medicine 60(12): 2325-2330
Massarotti, M.; Marchesoni, A.; Biondi, M.Louisa.; Marasini, B. 2002: Polymorphism in the matrix metalloproteinase-1 promoter gene and severity of rheumatoid arthritis Journal of Rheumatology 29(10): 2241; Author Reply 2242
Ma, J.; Wang, X.; Mo, Y.; Chen, L.; Zheng, D.; Wei, X.; Dai, L. 2015: Value of serum matrix metalloproteinase-3 in the assessment of active disease in patients with rheumatoid arthritis Zhonghua Yi Xue Za Zhi 95(47): 3823-3828
Ichikawa, Y.; Yamada, C.; Horiki, T.; Hoshina, Y.; Uchiyama, M. 1998: Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis Clinical and Experimental Rheumatology 16(5): 533-540
Kawaguchi, H. 2000: Osteoclastic bone resorption in joint destruction of rheumatoid arthritis Ryumachi 40(1): 32-38
Cheung, N.T.; Dawes, P.T.; Poulton, K.V.; Ollier, W.E.; Taylor, D.J.; Mattey, D.L. 2000: High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis Journal of Rheumatology 27(4): 882-887
Gotoh, H.; Yamada, H.; Yoshihara, Y.; Kikuchi, T.; Obata, K.; Shinmei, M. 1997: Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis Ryumachi 37(1): 3-8
Tebib, J.G.; Boughaba, H.; Letroublon, M.C.; Bienvenu, J.; Noel, E.; Armanet, P.; Colson, F.; Roullet, A.; Bouvier, M. 1991: Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression European Cytokine Network 2(4): 239-243
Eguchi, K. 2005: Diagnosis and prediction of joint destruction found in patients with rheumatoid arthritis using by biochemical markers Nihon Rinsho. Japanese Journal of Clinical Medicine 63(9): 1586-1593
Yoshikawa, T.; Suzuki, K.; Kobayashi, O.; Sairenji, M.; Motohashi, H.; Yanoma, S.; Noguchi, Y.; Tsuburaya, A. 1998: Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(9): 1461-1464
Mafune, K. 2001: Matrix metalloproteinase (MMP), matrix serine proteinase (MSP), tissue inhibitor of metalloproteinase (TIMP) Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 6): 176-183
Yoshihara, Y.; Yamada, H. 2007: Matrix metalloproteinases and cartilage matrix degradation in rheumatoid arthritis Clinical Calcium 17(4): 500-508
Shimizu, M.; Yasuda, T.; Nakagawa, T.; Yamashita, E.; Julovi, S.M.; Hiramitsu, T.; Nakamura, T. 2003: Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines Journal of Rheumatology 30(6): 1164-1172
Zernicke, R.F.; Wohl, G.R.; Greenwald, R.A.; Moak, S.A.; Leng, W.; Golub, L.M. 1997: Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis Journal of Rheumatology 24(7): 1324-1331
Xu, S.; Ma, X-Xi.; Hu, L-Wei.; Peng, L-Ping.; Pan, F-Ming.; Xu, J-Hua. 2014: Single nucleotide polymorphism of RANKL and OPG genes may play a role in bone and joint injury in rheumatoid arthritis Clinical and Experimental Rheumatology 32(5): 697-704
Okada, Y.; Takeuchi, N.; Gonoji, Y.; Nakanishi, I.; Nagase, H.; Hayakawa, T. 1992: Simultaneous production of collagenase, matrix metalloproteinase 3 (stromelysin) and tissue inhibitor of metalloproteinases by rheumatoid synovial lining cells Matrix . Suppl 1: 398-399
Guo, L.-j.; Luo, X.-h.; Xie, H.; Zhou, H.-d.; Liao, E.-y. 2005: The effects of 1alpha,25-dihydroxyvitamin D3 in regulation matrix metalloproteinase and tissue metalloproteinase inhibitors in human osteoblasts Zhonghua Nei Ke Za Zhi 44(2): 125-128
Wang, H.; Tan, L.; Liu, J.; Li, Q.; Pan, Y.; Zhong, M. 2014: Effect of smokers'sera on Porphyromonas gingivalis internalizing KB cells and the expression of matrix metalloproteinase-1, -9 and tissue inhibitor of metalloproteinase-1 Zhonghua Kou Qiang Yi Xue Za Zhi 49(1): 15-20
Ziablitsev, S.V.; Korobova, A.V.; Petrenko, O.V.; Serduk, V.N.; Mogilevsky, S.U. 2016: Role of matrix metalloproteinase 9 and its tissue inhibitor 1 in development and prognosis of diabetic retinopathy Fiziolohichnyi Zhurnal 62(5): 37-44
Nanki, T. 2007: Molecular mechanisms of bone destruction in rheumatoid arthritis Clinical Calcium 17(4): 510-516